Urogen Pharma (NASDAQ:URGN) Releases Quarterly Earnings Results, Misses Estimates By $0.02 EPS

Urogen Pharma (NASDAQ:URGN) posted its quarterly earnings data on Wednesday. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.02), FiscalAI reports. The company had revenue of $72.46 million during the quarter, compared to analyst estimates of $63.55 million.

Here are the key takeaways from Urogen Pharma’s conference call:

• ZUSDURI revenue reached $50.4 million in Q2, up 73% sequentially, with 1,444 activated accounts, 452 prescribers, and repeat prescribers representing approximately 45% of writers. Community practices accounted for about 55% of utilization, supporting the company’s view that adoption remains in an early growth phase.
• UroGen reported durable ZUSDURI clinical results, with 64.5% of complete responders estimated to remain disease-free at 36 months and median response duration not yet reached. Management said real-world physician experience is increasingly supporting use beyond patients who are poor surgical candidates.
• JELMYTO revenue was stable at $22 million, and the company maintained its 2026 guidance of $97 million to $101 million. However, management has not yet observed a meaningful “reverse halo” effect from the ZUSDURI launch on JELMYTO demand.
• UroGen expects to submit the UGN-103 NDA within weeks, complete UGN-104 enrollment by year-end, and begin a UGN-501 Phase I study later in 2026. A patent allowance covering ZUSDURI and UGN-103 is expected to provide protection through July 2044.
• Full-year operating expense guidance increased to $260 million-$270 million as UroGen accelerates ZUSDURI promotional and patient-awareness spending and advances pipeline programs. Management remains confident it can reach profitability with existing capital resources, but the higher investment is expected to pressure near-term results.

Urogen Pharma Trading Up 12.9%

Shares of URGN traded up $5.17 during midday trading on Wednesday, reaching $45.09. The stock had a trading volume of 1,818,843 shares, compared to its average volume of 791,040. The firm has a 50 day simple moving average of $35.39 and a 200-day simple moving average of $26.61. Urogen Pharma has a one year low of $15.86 and a one year high of $47.84. The firm has a market cap of $2.20 billion, a PE ratio of -16.36 and a beta of 1.57.

Insider Activity

In related news, insider Mark Schoenberg sold 10,000 shares of the firm’s stock in a transaction dated Thursday, July 9th. The shares were sold at an average price of $40.00, for a total value of $400,000.00. Following the completion of the sale, the insider directly owned 119,763 shares in the company, valued at approximately $4,790,520. This trade represents a 7.71% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 25,222 shares of company stock valued at $892,661. 4.80% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in URGN. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Urogen Pharma by 7.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,320 shares of the company’s stock worth $258,000 after acquiring an additional 1,653 shares during the last quarter. Main Street Financial Solutions LLC boosted its position in Urogen Pharma by 8.2% during the second quarter. Main Street Financial Solutions LLC now owns 25,968 shares of the company’s stock worth $356,000 after purchasing an additional 1,968 shares during the period. Barclays PLC boosted its position in Urogen Pharma by 3.8% during the fourth quarter. Barclays PLC now owns 57,744 shares of the company’s stock worth $1,352,000 after purchasing an additional 2,125 shares during the period. Osaic Holdings Inc. increased its holdings in shares of Urogen Pharma by 491.2% in the second quarter. Osaic Holdings Inc. now owns 3,695 shares of the company’s stock valued at $50,000 after purchasing an additional 3,070 shares during the last quarter. Finally, Russell Investments Group Ltd. increased its holdings in shares of Urogen Pharma by 1,594.4% in the third quarter. Russell Investments Group Ltd. now owns 3,321 shares of the company’s stock valued at $66,000 after purchasing an additional 3,125 shares during the last quarter. 91.29% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

URGN has been the topic of a number of recent research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Urogen Pharma in a report on Friday, July 17th. HC Wainwright restated a “buy” rating on shares of Urogen Pharma in a report on Thursday, July 9th. Oppenheimer lifted their price target on shares of Urogen Pharma from $40.00 to $50.00 and gave the company an “outperform” rating in a research note on Thursday, July 16th. UBS Group reissued a “buy” rating on shares of Urogen Pharma in a research report on Thursday, July 9th. Finally, LADENBURG THALM/SH SH started coverage on Urogen Pharma in a report on Monday, May 11th. They issued a “buy” rating and a $43.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $41.62.

Urogen Pharma Company Profile

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.